Image source: Celator Pharmaceuticals.
Clinical stage drug-developer Celator Pharmaceuticals (NASDAQ: CPXX) has secured coveted breakthrough therapy designation from the FDA for Vyxeos, its novel treatment for acute myeloid leukemia (AML). The FDA status potentially accelerates the company’s timeline and helps clear the way toward potential commercialization of Vyxeos next year.